Diagnosis and management of iron deficiency anemia

Jacquelyn M. Powers, George R. Buchanan

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Iron deficiency anemia (IDA) is a common hematologic condition, affecting a substantial proportion of the world's women and young children. Optimal management of IDA requires an accurate diagnosis, identification and correction of the underlying cause, provision of medicinal iron therapy, and confirmation of treatment success. There are limited data to support current treatment approaches regarding oral iron preparation, dosing, monitoring, and duration of therapy. New intravenous iron agents have improved safety profiles, which may foster their increased utilization in the treatment of patients with IDA. Clinical trials focused on improving current treatment standards for IDA are sorely needed.

Original languageEnglish (US)
Pages (from-to)729-745
Number of pages17
JournalHematology/Oncology Clinics of North America
Volume28
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Iron-Deficiency Anemias
Iron
Therapeutics
Clinical Trials
Safety

Keywords

  • Anemia
  • Deficiency
  • IDA
  • Iron
  • Microcytic
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Diagnosis and management of iron deficiency anemia. / Powers, Jacquelyn M.; Buchanan, George R.

In: Hematology/Oncology Clinics of North America, Vol. 28, No. 4, 2014, p. 729-745.

Research output: Contribution to journalArticle

@article{b0948a85ba804f1f910af054ff82b387,
title = "Diagnosis and management of iron deficiency anemia",
abstract = "Iron deficiency anemia (IDA) is a common hematologic condition, affecting a substantial proportion of the world's women and young children. Optimal management of IDA requires an accurate diagnosis, identification and correction of the underlying cause, provision of medicinal iron therapy, and confirmation of treatment success. There are limited data to support current treatment approaches regarding oral iron preparation, dosing, monitoring, and duration of therapy. New intravenous iron agents have improved safety profiles, which may foster their increased utilization in the treatment of patients with IDA. Clinical trials focused on improving current treatment standards for IDA are sorely needed.",
keywords = "Anemia, Deficiency, IDA, Iron, Microcytic, Therapy",
author = "Powers, {Jacquelyn M.} and Buchanan, {George R.}",
year = "2014",
doi = "10.1016/j.hoc.2014.04.007",
language = "English (US)",
volume = "28",
pages = "729--745",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Diagnosis and management of iron deficiency anemia

AU - Powers, Jacquelyn M.

AU - Buchanan, George R.

PY - 2014

Y1 - 2014

N2 - Iron deficiency anemia (IDA) is a common hematologic condition, affecting a substantial proportion of the world's women and young children. Optimal management of IDA requires an accurate diagnosis, identification and correction of the underlying cause, provision of medicinal iron therapy, and confirmation of treatment success. There are limited data to support current treatment approaches regarding oral iron preparation, dosing, monitoring, and duration of therapy. New intravenous iron agents have improved safety profiles, which may foster their increased utilization in the treatment of patients with IDA. Clinical trials focused on improving current treatment standards for IDA are sorely needed.

AB - Iron deficiency anemia (IDA) is a common hematologic condition, affecting a substantial proportion of the world's women and young children. Optimal management of IDA requires an accurate diagnosis, identification and correction of the underlying cause, provision of medicinal iron therapy, and confirmation of treatment success. There are limited data to support current treatment approaches regarding oral iron preparation, dosing, monitoring, and duration of therapy. New intravenous iron agents have improved safety profiles, which may foster their increased utilization in the treatment of patients with IDA. Clinical trials focused on improving current treatment standards for IDA are sorely needed.

KW - Anemia

KW - Deficiency

KW - IDA

KW - Iron

KW - Microcytic

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84904796630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904796630&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2014.04.007

DO - 10.1016/j.hoc.2014.04.007

M3 - Article

C2 - 25064710

AN - SCOPUS:84904796630

VL - 28

SP - 729

EP - 745

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 4

ER -